T2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease

dc.contributor.authorAlcazar-Navarrete, Bernardino
dc.contributor.authorManuel Diaz-Lopez, Jose
dc.contributor.authorGarcia-Flores, Paula
dc.contributor.authorOrtega-Antelo, Marina
dc.contributor.authorAguilar-Cruz, Ivan
dc.contributor.authorRuiz-Rodriguez, Oliverio
dc.contributor.authorSantiago-Diaz, Pablo
dc.contributor.authorRomero Palacios, Pedro Jose
dc.contributor.authoraffiliation[Alcazar-Navarrete, Bernardino] HU Virgen de las Nieves, Resp Dept, Granada, Spain
dc.contributor.authoraffiliation[Manuel Diaz-Lopez, Jose] HU Virgen de las Nieves, Resp Dept, Granada, Spain
dc.contributor.authoraffiliation[Garcia-Flores, Paula] HU Virgen de las Nieves, Resp Dept, Granada, Spain
dc.contributor.authoraffiliation[Ortega-Antelo, Marina] HU Virgen de las Nieves, Resp Dept, Granada, Spain
dc.contributor.authoraffiliation[Ruiz-Rodriguez, Oliverio] Hosp Alta Resolut Loja, Agenda Sanitaria Hosp Poniente, Resp Dept, AIG Med, Granada, Spain
dc.contributor.authoraffiliation[Santiago-Diaz, Pablo] Hosp Alta Resolut Loja, Agencia Sanitaria Hosp Poniente, Cardiol Dept, AIG Med, Granada, Spain
dc.contributor.authoraffiliation[Alcazar-Navarrete, Bernardino] Univ Granada, Fac Med, Granada, Spain
dc.contributor.authoraffiliation[Romero Palacios, Pedro Jose] Univ Granada, Fac Med, Granada, Spain
dc.contributor.authoraffiliation[Alcazar-Navarrete, Bernardino] Ctr Invest Biomed Red Enfermedades Respiratorias, Madrid, Spain
dc.contributor.authoraffiliation[Aguilar-Cruz, Ivan] Hosp Clin San Cedlio, Emergency Dept, Granada, Spain
dc.contributor.funderNeumosur Foundation
dc.date.accessioned2025-01-07T12:43:19Z
dc.date.available2025-01-07T12:43:19Z
dc.date.issued2022-08-01
dc.description.abstractIntroduction: Type 2 (T2) biomarkers such as blood eosinophil count (BEC) and FeNO have been related to a higher risk of exacerbations in COPD. It is unknown whether combining these biomarkers could be useful in forecasting COPD exacerbations. Methods: COPD patients were enrolled in this prospective, multicenter, observational study and followed up for 1 year, during which BEC were analysed at baseline (V0) while FeNO analyses were performed at baseline (V0), 6 months (V1) and 12 months (V2). The risk of moderate or severe exacerbation during follow up was assessed by Cox regression analysis, and the predictive capacity of both measurements was assessed by ROC curves and the DeLong test. Statistical significance was assumed at P
dc.identifier.doi10.1016/j.arbres.2021.11.006
dc.identifier.essn1579-2129
dc.identifier.issn0300-2896
dc.identifier.pmid35312535
dc.identifier.urihttps://hdl.handle.net/10668/24872
dc.identifier.wosID862248000006
dc.issue.number8
dc.journal.titleArchivos de bronconeumologia
dc.journal.titleabbreviationArch. bronconeumol.
dc.language.isoen
dc.organizationSAS - Hospital de Poniente
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationSAS - Hospital Universitario Virgen de las Nieves
dc.organizationSAS - Hospital Universitario San Cecilio
dc.page.number595-600
dc.publisherElsevier espana slu
dc.subjectCOPD
dc.subjectType 2 inflammation
dc.subjectBiomarkers
dc.subjectFe NO
dc.subjectEosinophil
dc.subjectBlood eosinophils
dc.subjectMortality
dc.subjectRisk
dc.titleT2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease
dc.typeresearch article
dc.volume.number58
dc.wostypeArticle

Files